Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/24/2012 | 05:51pm CET

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 
   Of  
 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
01/16 MERCK : Drives Business Opportunities in the U.S. to Foster Innovation Across al..
01/13 MERCK : Introduces New Calibration Kit for In Vitro Diagnostic Use
01/12 MERCK : MilliporeSigma Kicks Off Year-Long ‘Curiosity Cube™’ T..
01/12 MERCK : and MD Anderson Cancer Center Enter Three-Year Strategic Collaboration
01/11 MERCK : Licenses Four Oncology Research and Development Programs from Vertex and..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Entry into a Material ..
01/11 MERCK : MilliporeSigma Expands End-to-End Biodevelopment Centers in North Americ..
01/10 MERCK : and CLEARink Displays Sign Development Agreement
01/04 MERCK : Cancer treatment co ARTSaVIT raises $6.3m
01/04 MERCK : Acquires BioControl to Strengthen Position in Food Safety Testing
More news
Sector news : Specialty & Advanced Pharmaceuticals
08:40aDJASTRAZENECA : Sets New Deadlines for MYSTIC Trial
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
01/12 Vertex And German Merck Find Their Perfect Fit
01/12 JPMorgan Day Three Roundup - Trump Reminds The Sector Who's In Charge
01/11 Vertex to collaborate with Germany's Merck in oncology
01/10 German Merck Unveils Its Secret Weapon
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Financials (€)
Sales 2016 15 044 M
EBIT 2016 3 509 M
Net income 2016 1 706 M
Debt 2016 11 023 M
Yield 2016 1,21%
P/E ratio 2016 25,59
P/E ratio 2017 22,67
EV / Sales 2016 1,61x
EV / Sales 2017 1,42x
Capitalization 13 176 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108 €
Spread / Average Target 6,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA2.82%14 037
ABBVIE INC-1.01%100 740
KYOWA HAKKO KIRIN CO L..-0.80%8 164
JAZZ PHARMACEUTICALS P..7.59%7 025
MALLINCKRODT PLC1.65%5 361
ZHANGZHOU PIENTZEHUANG..-1.88%3 986
More Results